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Histopathological audit of positive circumferential resection margins (CRMs) can be used as a surrogate measure of the success of
rectal cancer treatment. We audited CRM involvement in rectal cancer patients and the impact of the multidisciplinary team (MDT)
on implementing a magnetic resonance imaging (MRI)-based preoperative treatment strategy. Data were collected on all newly
diagnosed rectal cancer patients treated in our network between January 1999 and December 2002. Data were analysed for MRI
prediction and histopathological assessment of CRM together with the MDT meeting treatment decisions. The CRMþve rate of
those discussed at MDT vs those not discussed were compared. We re-audited the CRMþve rates 1 year after introducing a policy
of mandatory preoperative MRI-based MDT discussion. Of the 298 patients diagnosed with rectal cancer, 39 (13%) were deemed
palliative, 178 underwent surgery alone and 81 underwent neoadjuvant therapy. Of these, 62 out of 178 patients underwent surgery
alone without MRI-based MDT discussion resulting in positive CRM in 16 cases (26%) as compared to 1 out of 116 (1%) in those
patients with MDT discussion of MRI. Overall CRMþve rate in all nonpalliative patients with or without MDT discussion was 12.5%
(32 out of 256), significantly lower than the o20% rate (Po0.001) quoted in national guidelines. Re-audit in 98 consecutive patients
following a change of policy produced a lower CRMþve rate of 3% (1 out of 37) for all surgery alone patients and an overall
CRMþve rate of 7% (5 out of 70). In conclusion, MDT discussion of MRI and implementation of a preoperative treatment strategy
results in significantly reduced positive CRM in rectal cancer patients.
British Journal of Cancer (2006) 94, 351–357. doi:10.1038/sj.bjc.6602947 www.bjcancer.com
& 2006 Cancer Research UK
Keywords: magnetic resonance imaging; rectal cancer; chemoradiotherapy; multidisciplinary team; circumferential resection margin
                                                 
The Colorectal Cancer Multidisciplinary Team (MDT) is composed
of specialist surgeons, clinical and medical oncologists, radio-
logists, histopathologists and specialist nurses. The MDT should
implement an agreed treatment strategy in rectal cancer patients
based on nationally accepted guidelines with the aim of
standardising and improving outcomes (2001; 2004). Currently,
there is no published data to support the central role of the MDT
discussion in effecting improved outcomes.
The main outcome measures of rectal cancer treatment have
traditionally been the local recurrence rates, the development of
distant metastases and overall survival. More recently, the
circumferential resection margin (CRM) has been identified as
an indicator of the quality of surgery within a unit, and there is
now good evidence to relate the CRM status to improved outcomes
(Birbeck et al, 2002; Nagtegaal et al, 2002). A positive CRM can be
defined as the histological identification of tumour within 1mm
surgical resection margin. The presence of a positive CRM has
been shown to correlate with an increasing incidence of local
recurrence, systemic failure and poor survival (Hall et al, 1998;
Delaney et al, 2002; Nagtegaal et al, 2002). However, some
published data have defined a positive CRM as the presence of
tumour within 2mm of the surgical resection margin as a more
accurate predictor of poor survival (Beets-Tan et al, 2001;
Nagtegaal et al, 2002; Marijnen et al, 2003).
In addition to CRM status, increasing depth of spread has also
been identified as a poor prognostic factor based on an analysis of
853 patients in the Erlangen Registry of Colorectal Carcinomas. In
this study, the prognostic value of the depth of invasion beyond
the bowel wall reported that extramural spread X5mm resulted in
a markedly reduced 5-year survival of 54% because of systemic
failure as compared to 85% in those with extramural spread
o5mm (Merkel et al, 2001). Other important poor prognostic
features include N2 nodal disease (four or more involved nodes),
T4 disease and extramural venous invasion (Shepherd et al, 1995).
High spatial resolution magnetic resonance imaging (MRI) has
achieved good accuracy in the preoperative prediction of positive
CRM, depth of extramural spread and other poor prognostic
features suggestive of locally advanced disease (Brown et al, 2003).
Such imaging can identify patients at high risk of local and
systemic failure in whom a preoperative treatment strategy could
be beneficial.
There is good evidence from the Dutch TME Trial that
preoperative short-course radiotherapy does not compensate for
positive resection margins (Marijnen et al, 2001; Marijnen et al,
2003). Therefore, it has been our policy to proceed with surgery
alone if MRI shows favourable prognostic features and to employ
neoadjuvant chemoradiotherapy as a means of inducing regression
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sin locally advanced rectal cancers (Janjan et al, 1999; Chau et al,
2003). The effectiveness of this approach can be judged by auditing
the histological CRM ve rates. Such rates can reflect the success of
the MDT process in addition to the effectiveness of the
implementation of established guidelines.
The aim of this study was to audit the CRMþve rates in rectal
cancer patients treated within our network after MDT discussion
of MRI and implementation of an appropriate preoperative
treatment strategy.
PATIENTS AND METHODS
A database was compiled of all consecutive biopsy-proven primary
rectal cancer patients treated within our network, between January
1999 and December 2002. The network consists of four hospitals
and six specialist colorectal surgeons. The data were collected from
the preoperative MDT meeting minutes, histopathology records
and MRI reports. For each case, it was noted whether an MRI had
been performed and whether the case had been discussed
preoperatively at an MDT meeting. Our network staging policy
required a pelvic MRI and abdominal computerised tomography
(CT) with either CXR or CT thorax to determine the presence of
metastatic disease. Patients were deemed palliative if they had
metastatic disease unsuitable for resection or significant comor-
bidity that precluded any therapeutic intervention.
Magnetic resonance imaging was used to categorise nonpallia-
tive patients into three groups according to prognostic features:
Group 1. The primary tumour showed good prognostic features
with potentially negative CRM. Such features included T1 and T2
tumours (except those low tumours described in Group 3) and T3
tumours with a depth of extramural spread less than 5mm
together with less than four nodes involved with tumour and no
evidence of extramural vascular invasion (Figure 1).
Group 2. The primary tumour showed any poor prognostic
features with potentially negative CRM. Such poor prognostic
features included peritoneal involvement (T4 disease), T3 tumours
with extramural depth of spread X5mm, presence of extramural
vascular invasion and four or more involved lymph nodes
(Figure 2).
Group 3. The primary tumour showed potentially positive CRM
(including full thickness T2 tumours arising below the origin of the
levator ani muscles), which is known to be associated with a higher
rate of margin positivity and therefore a worse outcome (Table 1)
(Figure 3). (During abdomino-perineal resection, there is a
tendency for the plane of dissection to ‘waist’ below the level of
the levators and a wide cylindrical dissection may be difficult to
achieve. This has translated into unacceptable levels of local
recurrence and involved margins. Hence, very low T2 tumours
have been incorporated into the worst prognosis treatment group.)
Margin positive disease was defined on MRI as tumour
extending to within 1mm or beyond the mesorectal fascia which
forms the surgical resection margin in total mesorectal excision
(TME) surgery.
Our local treatment stratification was based on evidence of:
  Five-year survival rates of 85% for rectal cancer patients with T3
tumours o5mm depth of extramural spread vs 54% survival for
cases with T3 Z5mm spread (Merkel et al, 2001).
  Peritoneal involvement is a known poor prognostic factor for
rectal cancers (Shepherd et al, 1995).
  Increasing percentage of nodal disease reduces overall survival
in colorectal cancer (Stocchi et al, 2001).
  EMV has been shown to be an independent poor prognostic
factor in colorectal cancer (Conroy et al, 1994; Mulcahy et al,
1997).
MRI technique
Only T2-weighted sequences were used. Magnetic resosnance
imaging was performed on a 1.5T scanner with a four-element
pelvic phased array wrap-around surface coil in the primary
hospital. All patients were imaged in the supine position. Neither
intravenous antiperistaltic agents or contrast agents were adminis-
tered. A coronal localising image was obtained to select axial and
sagittal images with a T2-weighted FSE sequence (TR 43000ms,
TE¼128ms, ETL¼16, 5mm thickness, four signal averages, scan
duration 3–5min). The sagittal images were used to plan 3mm
oblique high spatial resolution axial images. The images were
acquired in a plane orthogonal to the tumour and rectal wall using
a T2-weighted FSE sequence (TR43000, TE¼128ms, 256 256
matrix, ETL ¼16, FOV¼16–18cm). Depending on the length of
tumour, scan duration was between 6 and 12min.
Chemoradiation regime
Patients received protracted venous infusion 5-fluorouracil (5-FU)
(300mgm
 2day
 1 for 12 weeks) with mitomycin C (7mgm
 2, i.v.
Figure 1 Example of a good prognosis tumour (Group 1). Axial T2-
weighted high-resolution image showing an annular tumour with no
evidence of extramural spread, no suspicious lymph nodes and clear
potential resection margins.
Figure 2 Example of a bad prognosis tumour showing EMV but
CRM ve (Group 2). Axial T2-weighted image showing tumour extending
into an extramural vein; the distance of tumour to the potential
circumferential margins, however, is 41mm, so the margins are considered
safe.
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sbolus every 6 weeks). Starting on week 13, 5-FU was reduced to
200mgm
 2day
 1 and concomitant pelvic radiotherapy 45Gy in 25
fractions was commenced followed by 5.4–9Gy boost to tumour
bed. Surgery was planned 6 weeks after chemoradiation (Chau
et al, 2003).
Any patient deemed eligible for neoadjuvant treatment on the
basis of poor prognostic disease or involved margins but with
contraindications to chemotherapy underwent long course radio-
therapy (LRT) alone. As with the chemoradiotherapy group,
surgical resection was planned 6 weeks following therapy. For the
purposes of analysis, the LRT patients were included in the
relevant neoadjuvant treatment groups on an intention to treat
basis.
Surgical technique
All surgical resections were performed with curative intent. The
operations performed included Hartmann’s procedure, high
anterior resection, low anterior resection with TME and loop
ileostomy and abdomino-perineal resection. The decision with
regard to the most appropriate operation was based on site of
tumour together with patient characteristics (including ano-rectal
physiology if deemed necessary) and surgeon’s preference.
Histopathological technique
Histopathology examinations were performed according to the
Royal College of Pathologists guidelines (Quirke and Williams,
1998). The CRM was defined as positive if tumour was within
1mm of the surgical resection margin. In cases of complete
histopathological response of tumour to neoadjuvant therapy,
multiple representative axial slices were taken throughout the
rectal specimen. T-stage, N-stage, CRM status and depth of
extramural invasion were documented for the purposes of the
study.
Analysis
The CRMþve rate of those discussed at MDT vs those not
discussed were compared using the kappa test. The 95%
confidence intervals (95% CI) were calculated using the binomial
distribution. Circumferential resection margin rates were com-
pared to national standards of o20% (2004) and published
CRMþve rates of 28% (Birbeck et al, 2002), using the binomial
distribution.
Closure of the audit loop
The results of the audit were presented to the multidisciplinary
team and since then, it has been mandated that all rectal cancer
patients and their MRIs be discussed by the MDT. A re-audit was
conducted from October 2003 to July 2004, following the
introduction of this new directive. The same treatment stratifica-
tion groups were used as described above.
RESULTS
Between January 1999 and December 2002, 298 patients diagnosed
with biopsy-proven adenocarcinoma of the rectum were treated
within the network. Median age was 67 years (range: 28–88 years)
and 58% were male. Thirty-nine patients (13%) were classified as
palliative either because of irresectable metastatic disease or
significant comorbidity that precluded therapeutic intervention –
not all these cases were discussed at MDT. Thus, 259 patients
(87%) were identified as eligible for potentially curative therapy
(Figure 4). One hundred and ninety-seven patients (76%) under-
went preoperative discussion following an MRI and of these 81
(41%) were referred for preoperative neoadjuvant therapy on the
basis of having poor prognostic features or a threatened or
involved CRM (Groups 2 and 3). Of the 81 patients undergoing
neoadjuvant treatment, six patients had contraindications to
chemotherapy and therefore underwent LRT. All six of these
patients proceeded to surgical resection.
The audit identified 62 out of 259 (24%) patients who proceeded
to surgery alone without preoperative MDT discussion of MRI. In
addition, 116 patients with good prognosis tumours were
discussed preoperatively and deemed suitable for primary surgery.
However, two of these patients refused surgery (Figure 4). Of the
Table 1 Locally agreed treatment policy for rectal cancer within the MDT
Treatment group MRI features Treatment strategy
1 T1–T2/T3 o5mm, N0/N1, predicted CRM ve Surgery alone (TME)
2T 3 Z5mm/T4, N2, predicted CRM ve Preoperative chemoradiotherapy
a
3 Predicted CRM+ve
b Preoperative chemoradiotherapy
a
Our local treatment stratification was based on evidence of 5-year survival rates of 85% for rectal cancer patients with T3 tumours o5mm depth of extramural spread vs 54%
survival for cases with T3 X5mm spread (Merkel et al, 2001). MDT¼multidisciplinary team; MRI¼magnetic resonance imaging; TME¼total mesorectal excision.
aPatients with
contraindications to the use of systemic chemotherapy were offered LRT as a preoperative treatment.
bDefined as tumour within 1mm of the mesorectal fascia or 4T2 tumour
arising from below the level of the origin of the levator muscles (Figure 1).
Figure 3 Example of a potential CRMþve tumour (Group 3). Axial T2-
weighted image depicting and annular infiltrating tumour. Tumour extend
to the mesorectal fascia anteriorly (arrow), the potential circumferential
resection margins are therefore considered involved.
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s62 patients undergoing surgery alone without an MDT discussion,
the CRMþve rate was 26% (95% CI¼16.6–39.7%) (Figure 4).
This contrasts with a 1% CRMþve rate (1 out of 116) in those
patients undergoing surgery alone after MDT discussion. Even the
inclusion of the two patients who refused surgery as presumed
CRMþve data would still only increase the CRMþve rate in this
group to 3% (3 out of 116) (Figure 4).
Of the 81 patients undergoing neoadjuvant therapy, 21 were in
Group 2 (Figure 5) including three patients who underwent LRT.
One patient refused surgery after a complete response to
preoperative neoadjuvant therapy as determined by MRI. There
were no positive margins in Group 2 (Figure 5). Of the 60 patients
in Group 3, the predicted margin positive group, only 12 patients
(20 %) remained unresectable following completion of preopera-
tive neoadjuvant therapy (two of these had received LRT only). Of
the 48 patients (80%) who proceeded to resection, only three were
CRMþve following resection (Figure 5). Therefore, out of the 60
patients in group 3, 45 (75%) achieved a negative CRM.
MRI prediction of appropriate treatment group in the surgery
alone patients was correct in 93% (106 out of 114). Of the
incorrectly predicted patients, 6% (7 out of 114) had one or more
poor prognostic feature identified histologically following resec-
tion. The remaining patient had a tumour perforation at the time
of surgery, which could not have been predicted preoperatively.
Table 2 shows the MRI predicted prognostic groupings and the
final actual prognostic groups as determined by histology. The
predicted CRMþve rate was 30% in patients undergoing MDT
discussion of MRI. However, on the final histology following
preoperative neoadjuvant therapy in Groups 2 and 3, there has
been considerable downstaging with 152 (77%) of tumours
demonstrating good prognostic features. This contrasts with
Table 3, the histological staging of patients who did not undergo
MDT discussion of MRI. Within this group, it can be seen that had
these patients been discussed at MDT, it is likely that 32 (52%)
would have been offered preoperative neoadjuvant therapy if the
network guidelines had been followed, and a corresponding
reduction in CRM positivity could have been anticipated. There
was no significant difference between the predicted CRM positivity
rate in the discussed group (60 out of 197, 30%) and the
Total no. rectal cancer patients 
298 
Potentially curative  
259 (87%) 
Not discussed 
62 (24%) 
Discussed 
197 (76%) 
Palliative cases 
39 (13%) 
Preoperative therapy 
(Groups 2 and 3) 
81 (41%) 
Surgery alone 
(Group 1) 
116 (59%) 
Surgery alone 
62 (100%) 
Refused surgery 
2/116 (2%) 
Histological 
CRM+ve 
16/62 (26%) 
Histological  
CRM–ve 
46/62 (74%) 
Histological  
CRM+ve 
1/116 (1%) 
Histological  
CRM–ve 
113/116 (97%) 
Figure 4 Actual treatment allocation.
Preoperative therapy 
81 (31%) 
Discussed (Group 2) 
21 (26%) 
Preoperative therapy 
60 (74%) 
Refused surgery 
1  
Resected 
20 (95%) 
Resected 
48 (80%) 
Irresectable 
12 (20%) 
Histological 
CRM+ve 
0 (0%) 
Histological 
CRM–ve 
20 (100%) 
Histological 
CRM–ve 
45/60 (75%) 
Histological 
CRM+ve 
3/60 (5%) 
Effective histological CRM+ve 
15/60 (25%) 
Figure 5 Histological CRM status in patients undergoing chemora-
diotherapy.
Table 2 Comparison of MRI predicted stage and final histological stage
in discussed patients
MRI staging of patients with MDT discussion of MRI
T1–T2, T3 o5mm, N0-1, CRM ve 116 (59%)
T3 X5mm, T4, N2, CRM ve 21 (11%)
CRM+ve 60 (30%)
Total 197
Final histological staging in resected patients with MDT discussion of
MRI
T1–2, T3o5mm, N0-1, CRM ve 152 (77%)
T3X5mm, T4, N2, CRM ve 26 (13%)
CRM+ve 4 (2%)
Unresected patients 15 (8%)
Total 197
MDT¼multidisciplinary team; MRI¼magnetic resonance imaging.
Table 3 Histopathological staging of patients who did not undergo MDT
discussion of MRI
Histopathology of patients undergoing surgery alone without MDT
discussion of MRI
T1–T2, T3 o5mm, N0-1, CRM ve 30 (48%)
T3X5mm, T4, N2, CRM ve 16 (26%)
CRM+ve 16 (26%)
Total 62
MDT¼multidisciplinary team; MRI¼magnetic resonance imaging.
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shistological CRM positivity rate in the nondiscussed group (16 out
of 62, 26%) (P¼0.483) (Tables 2 and 3).
The CRMþve rate for all patients undergoing surgery alone
whether discussed or not was 9.5% (17 out of 180). Overall, there
was a 2% CRMþve rate (4 out of 182) in all resected patients
discussed at MDT. If the 12 patients with irresectable disease were
included together with the patients refusing surgery, the cumula-
tive CRMþve rate was 8% (16 out of 197). Therefore, the
CRMþve rate for all patients who underwent MDT discussion
following an MRI (8%) is significantly lower than those patients
not discussed (8 vs 26%) (Po0.001). These rates can be compared
to national figures (2004) (8 vs o20%) (Po0.001). However, if we
include those patients not discussed at MDT, the overall CRMþve
rate becomes 12.5% (32 out of 259), which is still well below
recognised guidelines (2004).
The re-audit (closure of the audit loop) identified 98 rectal
cancer patients in a 10-month period from the same catchment
area under the care of the original six surgeons. Twenty-four of
ninety-eight patients (24%) were deemed palliative after MDT
discussion on the basis of irresectable metastatic disease or
profound co-morbidity (Figure 6). Of the 74 patients deemed
potentially curative, only three patients (4%) did not undergo MRI
or MDT discussion (Figure 6). All of these patients proved to be
CRM ve on histology. Seventy-one of seventy-four potentially
curative patients did undergo MDT discussion of MRI. Thirty-four
of these underwent surgery alone and of these, 33 were proven to
be CRM ve. Of the 37 patients selected for neoadjuvant therapy,
one patient died of a pulmonary embolus following a defunction-
ing colostomy before commencement of preoperative neoadjuvant
therapy. A further two patients died of cardiac problems during
the initial chemotherapy and one patient refused treatment. Of the
remaining patients, 30 underwent resection after preoperative
neoadjuvant therapy with 29 having negative circumferential
margins.
In the re-audit, the CRMþve rate was only 3% (1 out of 37) for
all surgery alone patients (i.e. including the three patients not
discussed). There was also a 3% CRMþve rate (2 out of 64) in all
resected patients discussed at MDT including those resected
following preoperative neoadjuvant therapy. If the three patients
with irresectable disease are included together with the patients
who died during preoperative neoadjuvant therapy, the cumulative
CRMþve rate is 7% (5 out of 71) in discussed patients.
The CRMþve rate for all re-audit patients who underwent MDT
discussion following an MRI (7%) is comparable to the original
audit of 8% (16 out of 197) and significantly lower than national
figures of o20% (2004) (Po0.001). Overall effective CRMþve
rates for all potentially curable patients – including those patients
with unresectable disease after preoperative neoadjuvant therapy
and those not discussed at MDT – was reduced from 12.5% (32 out
of 259) in the original audit to 7% (5 out of 71) in the re-audit.
DISCUSSION
The success of rectal cancer treatment has traditionally been
measured in terms of local recurrence rates and predicted survival
curves. However, definitions of local recurrence vary between
series (Anwar et al, 2001) and the recent demonstration of the role
of preoperative therapy has been directed at improving these
outcomes. The introduction of TME has reduced local recurrence
rates and these results have now been replicated (MacFarlane et al,
1993; Havenga et al, 1999; Cecil et al, 2004).
The debate over preoperative vs postoperative radiotherapy has
been resolved (Sauer et al, 2004) and neoadjuvant therapy with
either chemoradiation or long course chemotherapy has emerged
as an effective treatment in the downstaging/downsizing of locally
advanced tumours (Chau et al, 2003; Rodel et al, 2003). This has
resulted in a greater proportion of patients being considered for
curative resection (Janjan et al, 1999; Chau et al, 2003). In our
series, 60 out of 259 potentially curative cases (23%) would have
traditionally been deemed inoperable based upon local invasion
and tumour fixity, but 45 (75%) of these underwent a CRM ve
resection following preoperative neoadjuvant therapy. Although
these results are encouraging, long-term follow-up of these
patients is required to determine the success of the strategy in
maintaining local and systemic control. Some evidence addressing
the issue of long-term follow-up is already available from a
multicentre retrospective study of 541 patients with locally
advanced rectal cancer undergoing preoperative CRT than surgical
resection, with 41% of CRMþve patients (48 out of 115)
developing local recurrence as compared to only 7% (31 out of
426) CRM ve patients after 17–37 months (Sebag-Montefiore
et al, 2005).
From review of the notes of patients in the original audit without
MDT discussion of MRI, it appears there was a combination of
factors accounting for their suboptimal management. Twenty of
these cases (32%) underwent an MRI, which was not reviewed
preoperatively at an MDT – subsequent review of these images
demonstrates that poor prognostic features could be identified in
10 cases (50%). Review of the original reports indicates under-
staging in some cases and could reflect the learning curve of MRI
reporting for rectal cancer in less experienced radiologists. This
highlights the need for MDT discussion and review of the films to
aid identification of diagnostically challenging cases. In other
cases, the surgeon deemed the tumour resectable on clinical
examination but was concerned about impending obstruction
Total no. rectal cancer pts 
98 
Potentially curative 
74 (74%) 
Palliative 
24 (24%) 
Not discussed at MDT 
3 (4%) 
Discussed at MDT 
71(96%) 
CRM–ve 
3 (100%) 
Surgery alone 
34/71(48%)  CRT/LRT 
36/71(51%) 
CRM–ve 
33/34 
CRM+ve 
1/34 (3%) 
Died pre-CRT
1/37 (3%) 
Died on CRT 
2/37 (5%) 
Unresectable 
3/37 (8%) 
Resected 
30/37 (81%) 
Refused CRT 
1/37 (3%) 
Effective CRM+ve rate 
8/37 (22%) 
CRM+ve 
1/37 (3%) 
CRM–ve 
29/37 (78%) 
Figure 6 Flow chart of results of re-audit.
MRI directed MDT preoperative treatment strategy
S Burton et al
355
British Journal of Cancer (2006) 94, 351–357 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand therefore, failed to wait for the MRI report before proceeding
with surgery.
In the original audit, only 13% of patients were deemed
palliative as compared to 24% on re-audit. The identification of
a higher proportion of palliative patients in the re-audit may
reflect the introduction of the directive that all patients should be
discussed at MDT with more thorough staging and assessment of
irresectable metastatic disease and medical infirmity.
Circumferential resection margin rates are becoming established
as a short-term outcome measure of local recurrence, distant
metastases and poor survival (Adam et al, 1994; Hall et al, 1998;
Birbeck et al, 2002; Wibe et al, 2002). Routine histopathological
assessment of the CRM gives objective evidence of the effectiveness
of treatment of rectal cancer (Birbeck et al, 2002). National
randomised controlled therapeutic trials are using the CRM rate as
a short-term outcome measure (Marijnen et al, 2003). In the
literature, resections can be classified as ‘curative’ or ‘palliative’
without any obvious preoperative staging criteria or any standar-
disation of the criteria. Circumferential resection margin positive
rates of 25% have been reported in series of selected ‘curative’
resections (Adam et al, 1994). With the development of MRI, it is
now possible to accurately predict tumour stage and other
prognostic features such as nodal disease, depth of extramural
spread and the presence of vascular invasion (Brown et al, 1999,
2003; Botterill et al, 2001). Therefore, curative intent can be
determined preoperatively.
A reduction in CRM positivity should be the goal of colorectal
MDTs. Our CRMþve/irresectable rate of 8% (95% CI¼3.9–
11.4%) for this unselected and consecutive series of patients
having MDT discussion of MRI is significantly better than the
accepted national standards of o20% (2004). The guidelines
specify CRMþve rates of o20% in potentially curative cases but
excluding patients undergoing LRT (2004). This rate was compar-
able (7.4%) in the re-audit. However, the overall CRMþve rate for
all potentially curative patients including those without MDT
discussion of MRI in the original audit was 12.5%. This was
reduced to 7% in the re-audit after mandating preoperative
MRI-based MDT discussion of all rectal cancer patients. Our MDT
network strategy is based on identifying those patients curable by
surgery alone and intensifying treatment in those patients at risk of
local and systemic failure. Our results demonstrate the effective-
ness of an MRI-based MDT discussion in implementing pre-
operative treatment strategies. Discussion and demonstration of
the MRI findings in the presence of all the MDT members appears
more useful than issuing a standard report in which subtleties may
be missed.
In conclusion, it appears that the CRMþve rate is reducible,
but only in the presence of robust MRI staging, preoperative
MDT discussion of all the staging investigations, optimal
surgery, the availability of effective preoperative therapies and
standardised histopathology reporting with comprehensive data
collection.
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